Correlation Between West Pharmaceutical and Sharps Technology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both West Pharmaceutical and Sharps Technology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining West Pharmaceutical and Sharps Technology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between West Pharmaceutical Services and Sharps Technology, you can compare the effects of market volatilities on West Pharmaceutical and Sharps Technology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in West Pharmaceutical with a short position of Sharps Technology. Check out your portfolio center. Please also check ongoing floating volatility patterns of West Pharmaceutical and Sharps Technology.

Diversification Opportunities for West Pharmaceutical and Sharps Technology

-0.28
  Correlation Coefficient

Very good diversification

The 3 months correlation between West and Sharps is -0.28. Overlapping area represents the amount of risk that can be diversified away by holding West Pharmaceutical Services and Sharps Technology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sharps Technology and West Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on West Pharmaceutical Services are associated (or correlated) with Sharps Technology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sharps Technology has no effect on the direction of West Pharmaceutical i.e., West Pharmaceutical and Sharps Technology go up and down completely randomly.

Pair Corralation between West Pharmaceutical and Sharps Technology

Considering the 90-day investment horizon West Pharmaceutical Services is expected to generate 0.24 times more return on investment than Sharps Technology. However, West Pharmaceutical Services is 4.23 times less risky than Sharps Technology. It trades about 0.04 of its potential returns per unit of risk. Sharps Technology is currently generating about -0.02 per unit of risk. If you would invest  23,358  in West Pharmaceutical Services on September 11, 2024 and sell it today you would earn a total of  8,858  from holding West Pharmaceutical Services or generate 37.92% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

West Pharmaceutical Services  vs.  Sharps Technology

 Performance 
       Timeline  
West Pharmaceutical 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in West Pharmaceutical Services are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, West Pharmaceutical may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Sharps Technology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sharps Technology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

West Pharmaceutical and Sharps Technology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with West Pharmaceutical and Sharps Technology

The main advantage of trading using opposite West Pharmaceutical and Sharps Technology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if West Pharmaceutical position performs unexpectedly, Sharps Technology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sharps Technology will offset losses from the drop in Sharps Technology's long position.
The idea behind West Pharmaceutical Services and Sharps Technology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance